Measuring airway inflammation using the fraction of exhaled nitric oxide
Carol Stonham Nurse practitioner, Minchinhampton Surgery, Gloucestershire
Although asthma is a common respiratory condition, there is no standardised definition of the type, severity or frequency of symptoms, nor of the findings on investigation. Therefore, it is not possible to make evidence-based recommendations on how to diagnose patients with asthma. This article describes the use of the fraction of exhaled nitric oxide (FeNO) as a biomarker of airway inflammation, thereby assisting diagnosis of asthma in clinical practice. FeNO can also be used to monitor adherence to inhaled corticosteroid therapy.
Nursing Standard. 28, 3,35-39. doi: 10.7748/ns2013.09.28.3.35.e7822Peer review
This article has been subject to double blind peer review
Received: 29 April 2013
Accepted: 15 July 2013